Video

Dr Schinke on Talquetamab in Multiple Myeloma

Carolina D. Schinke, MD, discusses updated findings from the phase 1/2 MonumenTAL-1 trial in patients with multiple myeloma.

Carolina D. Schinke, MD, associate professor, medicine, Myeloma Center, University of Arkansas for Medical Sciences, discusses updated findings from the phase 1/2 MonumenTAL-1 trial (NCT04634552) in patients with multiple myeloma.

In MonumenTAL-1, patients with multiple myeloma who were treatment-naïve or relapsed/refractory to prior T-cell redirection therapy (TCR) received the GPRC5D-targeted bispecific antibody talquetamab at either 0.4 mg/kg weekly or 0.8 mg/kg every 2 weeks. Previous findings from this trial showed that, at a median follow-up of 11.7 months in the patients with relapsed/refractory disease who received the agent at 0.4 mg/kg and 4.2 months in those who received the agent at 0.8 mg/kg, the overall response rates (ORRs) were 70% and 64%, respectively.

At a data cutoff date of January 17, 2023, the ORRs were 74.1%, 71.7%, and 64.7% in patients who received talquetamab at 0.4 mg/kg, those who received the agent at 0.8 mg/kg, and those who had received prior TCR, respectively. Specifically, the ORR was 75.0% in patients who had received prior CAR T-cell therapy and 44.4% in those who had received prior bispecific antibodies. In the 0.4 mg/kg cohort, the very good partial response (VGPR), complete response (CR), and stringent complete response (sCR) rates were 25.9%, 9.8%, and 23.8%, respectively. In the 0.8 mg/kg cohort, the VGPR, CR, and sCR rates were 22.1%, 9.0%, and 29.7%, respectively. In the cohort of patients who had received prior TCR, the VGPR, CR, and sCR rates were 19.6%, 5.9%, and 29.4%, respectively.

At median follow-ups of 18.8 months, 12.7 months, and 14.8 months in patients who received talquetamab at 0.4 mg/kg, those who received the agent at 0.8 mg/kg, and those who had received prior TCR, the median durations of response (DORs) were 9.5 months (95% CI, 6.7-13.3), not reached (NR; 95% CI, 13.0 months-NR), and 11.9 months (95% CI, 4.8-NR), respectively, and the respective 12-month DOR rates in patients who achieved a CR or better were 78.9%, 90.5%, and 80.5%.

This novel bispecific antibody elicited impressive efficacy outcomes in patients with multiple myeloma, Schinke concludes.

Related Videos
David Samuel Dicapua Siegel, MD
Axel Hauschild, MD, PhD, head, Skin Cancer Trial Center, University Hospital Schleswig-Holstein
 Philip McCarthy, MD
Lova L. Sun, MD, MSCE
Robert M. Rifkin, MD, FACP
Ahmad Tarhini, MD, PhD
Allison Winter, MD
Rocio Garcia-Carbonero, MD
Andrew Ip, MD
Anthony B. El-Khoueiry, MD